Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT07022418RecruitingPhase 2
Formoterol for diabetic kidney disease
This trial tests if a drug called formoterol (usually used for asthma) can help protect the kidneys in people with type 2 diabetes and early-to-moderate kidney disease. It may offer a new way to slow kidney damage.
Charleston, South CarolinaAges 18–75 - NCT06994845RecruitingPhase 3
Testing iptacopan for children with IgA nephropathy
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Madera, CaliforniaAges 2–18 - NCT06989359RecruitingPhase 2
Study of ADX-038 for complement-related kidney disease
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
Doral, FloridaAges 18 years+ - NCT06963827RecruitingPhase 3
Study of mezagitamab for IgA nephropathy
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
Birmingham, AlabamaAges 18 years+ - NCT06954090Enrolling by invitationPhase 4
Urine test to guide early treatment in type 2 diabetes
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
Herlev, Hajdú-BiharAges 18 years+ - NCT06893328Recruiting
Real-world study of primary membranous nephropathy
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
Guangzhou, GuangdongAges 18 years+ - NCT06858319RecruitingPhase 3
Long-term study of zigakibart for IgA nephropathy
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Denver, ColoradoAges 18–100 - NCT06837181Recruiting
Understanding diabetes complications in cystic fibrosis
This study looks at how long-term diabetes affects people with cystic fibrosis. It helps researchers understand complications and improve care.
Birmingham, AlabamaAges 12 years+ - NCT06797518RecruitingPhase 2
Testing iptacopan for IgA nephropathy kidney changes
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
Birmingham, AlabamaAges 18–99 - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT05283512Recruiting
IV versus drink fluids to protect kidneys after CT scan
This study compares giving fluids through a vein versus drinking fluids to lower the risk of sudden kidney injury after a CT scan with contrast dye. It focuses on adults with very poor kidney function who are scheduled for an elective CT scan.
Odense C, FynAges 18 years+ - NCT06674577Enrolling by invitationPhase 2
Long-term safety study of atacicept for IgA nephropathy
This study looks at the long-term safety and effectiveness of atacicept in people with IgA nephropathy (IgAN) who have already completed treatment in a previous atacicept study. It is for patients who want to continue their care and see how well the medicine works over more time.
Brisbane, CaliforniaAges 18–99 - NCT06557265RecruitingPhase 1/Phase 2
NKX019 for lupus kidney disease or membranous nephropathy
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
Little Rock, ArkansasAges 18–75 - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Hollywood, FloridaAges 16 years+ - NCT05975671Recruiting
Survey in pediatric ICU to reduce upfront vancomycin use
This study is a survey and quality-improvement effort in participating children’s intensive care units. It aims to understand and change how doctors decide to start vancomycin (an antibiotic) when sepsis is suspected, to improve care and avoid unnecessary use.
Atlanta, GeorgiaAges Any age - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT06217302RecruitingPhase 3
Sotagliflozin for kidney protection in type 1 diabetes
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Stanford, CaliforniaAges 18–75 - NCT05692388Recruiting
Study social needs support for Black adults with kidney and diabetes
This study looks at health-related social needs—like barriers to food, housing, or care—in African American adults living with type 2 diabetes and chronic kidney disease. It uses a mixed-methods approach to understand needs better and what support may help.
Milwaukee, WisconsinAges 18 years+ - NCT04745728RecruitingPhase 3
Testing different immune-suppressing treatments for membranous kidney disease
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
Beijing, Beijing MunicipalityAges 18–80 - NCT04982419RecruitingPhase 2/Phase 3
Remote arm treatment to protect heart and kidneys in heart failure
This trial tests whether a simple “arm cuff” treatment done before a heart artery procedure can help protect the kidneys and the heart in people with congestive heart failure. If it works, it may lower the chance of kidney injury around the time of the scan/stent procedure.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05147831Recruiting
Remote arm treatment to prevent kidney injury from contrast dye
This trial tests whether a simple “arm conditioning” technique done remotely before a procedure can help prevent kidney injury caused by contrast dye used during certain heart catheter tests. You might benefit if you’re having a coronary angiogram and your kidney function is reduced, but you’re not on dialysis.
Galveston, TexasAges 18 years+ - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Los Angeles, CaliforniaAges 1–17
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 151 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.